Wolverine Asset Management LLC Acquires 5,769 Shares of NewAmsterdam Pharma (NASDAQ:NAMS)

Wolverine Asset Management LLC lifted its holdings in shares of NewAmsterdam Pharma (NASDAQ:NAMS) by 197.2% in the 4th quarter, HoldingsChannel.com reports. The fund owned 8,694 shares of the company’s stock after purchasing an additional 5,769 shares during the quarter. Wolverine Asset Management LLC’s holdings in NewAmsterdam Pharma were worth $97,000 as of its most recent filing with the Securities and Exchange Commission.

Separately, Schonfeld Strategic Advisors LLC raised its position in shares of NewAmsterdam Pharma by 12.9% in the third quarter. Schonfeld Strategic Advisors LLC now owns 64,700 shares of the company’s stock valued at $598,000 after purchasing an additional 7,400 shares during the period. 89.89% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In other news, Director Louis G. Lange acquired 5,000 shares of the business’s stock in a transaction that occurred on Tuesday, February 13th. The stock was acquired at an average price of $19.00 per share, with a total value of $95,000.00. Following the completion of the transaction, the director now directly owns 24,878 shares of the company’s stock, valued at approximately $472,682. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. In other news, Director James N. Topper purchased 8,429 shares of NewAmsterdam Pharma stock in a transaction dated Tuesday, March 26th. The shares were bought at an average cost of $21.50 per share, for a total transaction of $181,223.50. Following the completion of the acquisition, the director now owns 3,008,429 shares in the company, valued at approximately $64,681,223.50. The acquisition was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Louis G. Lange purchased 5,000 shares of the firm’s stock in a transaction on Tuesday, February 13th. The stock was acquired at an average price of $19.00 per share, with a total value of $95,000.00. Following the completion of the transaction, the director now owns 24,878 shares in the company, valued at approximately $472,682. The disclosure for this purchase can be found here. 2.50% of the stock is owned by company insiders.

NewAmsterdam Pharma Stock Up 2.6 %

Shares of NASDAQ NAMS opened at $21.99 on Monday. The business has a fifty day moving average price of $21.61 and a two-hundred day moving average price of $15.89. NewAmsterdam Pharma has a fifty-two week low of $5.63 and a fifty-two week high of $26.35.

Wall Street Analysts Forecast Growth

NAMS has been the subject of several research analyst reports. Royal Bank of Canada lifted their target price on shares of NewAmsterdam Pharma from $25.00 to $31.00 and gave the stock an “outperform” rating in a report on Thursday, February 29th. Guggenheim started coverage on NewAmsterdam Pharma in a report on Thursday, January 18th. They set a “buy” rating and a $30.00 price objective for the company. Piper Sandler assumed coverage on NewAmsterdam Pharma in a research report on Tuesday, January 16th. They issued an “overweight” rating and a $37.00 target price on the stock. Finally, Scotiabank initiated coverage on NewAmsterdam Pharma in a report on Thursday, March 14th. They set a “sector outperform” rating and a $35.00 price target for the company. Five research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus target price of $33.25.

NewAmsterdam Pharma Company Profile

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.